Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
Completed
United Therapeutics
Phase 4
2006-09-01
The purpose of this 8-week study is to compare the effects of switching from therapy with
epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing
to Remodulin will have on patient satisfaction with their treatment and impact on quality of
life.
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
Terminated
United Therapeutics
Phase 4
2007-02-01
The purpose of this 8-week study is to compare the effects of switching from intravenous
Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved
therapy for pulmonary arterial hypertension (PAH). Unlike Flolan, Remodulin does not need to
be mixed daily and is stable at room temperature, so there is no need for ice packs. In
addition, Remodulin is changed every 48hrs, instead of every 12-24 (with ice packs) or every
8 hours (without ice packs) with Flolan. Flolan is given using a type of portable medication
pump called the CADD Legacy infusion pump. In this study, Remodulin will be given using a
smaller and lighter medication pump called the Crono Five infusion pump. This study will also
assess the effect that changing to Remodulin will have on treatment satisfaction and patient
quality of life.
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
Terminated
United Therapeutics
Phase 4
2008-03-01
The purpose of this 8-week study is to compare the effects of switching from therapy with
epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing
to Remodulin will have on patient satisfaction with their treatment and impact on quality of
life.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.